BridgeBio Pharma Balance Sheet
NASDAQ: BBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
BridgeBio Pharma financial position
At the end of fiscal 2025, BridgeBio Pharma reported total assets of $936.0 million, up 1.8% from a year earlier against total liabilities of $3.01 billion. Shareholders' equity was negative at -$2.09 billion, meaning liabilities exceed assets; this is often the result of large share buybacks or accumulated losses. The company held $570.1 million in cash and equivalents against $2.01 billion of debt, a net debt position of $1.44 billion.
The current ratio (current assets divided by current liabilities) was 2.77, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
BridgeBio Pharma balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 570.12M | 681.10M | 375.94M | 376.69M | 393.77M | 356.08M | 363.77M | 436.09M | 92.00M |
| Short-Term Investments | 17.36M | 0 | 0 | 51.58M | 393.74M | 251.01M | 182.22M | — | — |
| Receivables | 139.44M | 4.72M | 1.75M | — | — | — | — | — | — |
| Inventory | 26.75M | 0 | — | — | — | — | — | — | — |
| Total Current Assets | 797.75M | 720.69M | 477.59M | 548.85M | 888.86M | 642.82M | 568.62M | 445.22M | — |
| Property, Plant & Equipment | 5.37M | 7.01M | 11.82M | 14.57M | 30.07M | 20.32M | 5.63M | 1.57M | — |
| Intangible Assets | 28.08M | 23.93M | 26.32M | 28.71M | 44.93M | 0 | — | — | — |
| Long-Term Investments | — | — | — | — | — | — | 31.14M | — | — |
| Total Assets | 936.02M | 919.34M | 546.38M | 623.04M | 1.01B | 703.59M | 631.68M | 464.94M | — |
| Accounts Payable | 36.23M | 9.62M | 10.65M | 11.56M | 11.88M | 8.95M | 8.85M | 13.51M | — |
| Short-Term Debt | — | — | — | — | — | 1.46M | — | — | — |
| Total Current Liabilities | 287.97M | 154.40M | 143.84M | 121.43M | 135.07M | 95.65M | 60.38M | 32.58M | — |
| Long-Term Debt | 2.01B | 437.34M | 446.44M | 430.99M | 430.75M | 92.42M | 91.79M | 54.51M | — |
| Total Liabilities | 3.01B | 2.38B | 1.89B | 1.87B | 1.88B | 595.70M | 155.70M | 87.58M | — |
| Shareholders' Equity | -2.09B | -1.47B | -1.35B | -1.25B | -870.41M | 57.91M | 408.45M | 314.88M | 85.85M |
| Retained Earnings | -3.82B | -3.10B | -2.56B | -1.92B | -1.44B | -888.75M | -440.03M | -179.44M | -48.70M |
| Total Debt | 2.01B | 437.34M | 446.44M | 430.99M | 430.75M | 93.88M | 91.79M | 54.51M | — |
| Net Cash (Debt) | -1.42B | 243.76M | -70.51M | -2.72M | 356.76M | 513.21M | 454.20M | 381.58M | 92.00M |
| Shares Outstanding | 194.77M | 190.04M | 175.08M | 150.63M | 147.34M | 122.85M | 123.66M | 92.06M | — |
This table shows 9 annual periods of BridgeBio Pharma's balance sheet, from FY 2025 back to FY 2017, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow BBIO's reporting calendar. What is a balance sheet?